{"title": "X-ray Structure of Main Protease of the Novel Coronavirus SARS-CoV-2 Enables Design of \u03b1-Ketoamide Inhibitors", "doi": "10.1101/2020.02.17.952879", "citation_id": "2020.02.17.952879v1", "date": "2020-02-20", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.02.17.952879", "abstract": "<p>A novel coronavirus has been identified as the causative agent of a massive outbreak of atypical pneumonia originating at Wuhan, Hubei province, China. Involved in the formation of the coronavirus replication complex, the viral main protease (Mpro, also called 3CLpro) represents an attractive target for therapy. We determined the crystal structure of the unliganded Mpro at 1.75 A resolution and used this structure to guide optimization of a series of alpha-ketoamide inhibitors. The main goal of the optimization efforts was improvement of the pharmacokinetic properties of the compounds. We further describe 1.95- and 2.20-A crystal structures of the complex between the enzyme and the most potent alpha-ketoamide optimized this way. These structures will form the basis for further development of these compounds to antiviral drugs.</p>", "twitter_description": "A novel coronavirus has been identified as the causative agent of a massive outbreak of atypical pneumonia originating at Wuhan, Hubei province, China. Involved in the formation of the coronavirus replication complex, the viral main protease (Mpro, also called 3CLpro) represents an attractive target for therapy. We determined the crystal structure of the unliganded Mpro at 1.75 \u00c5 resolution and used this structure to guide optimization of a series of alpha-ketoamide inhibitors. The main goal of the optimization efforts was improvement of the pharmacokinetic properties of the compounds. We further describe 1.95- and 2.20-\u00c5 crystal structures of the complex between the enzyme and the most potent alpha-ketoamide optimized this way. These structures will form the basis for further development of these compounds to antiviral drugs.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.17.952879v1.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.02.17.952879v1", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.17.952879v1.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/02/20/2020.02.17.952879.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.02.17.952879v1", "access_rights": "restricted", "authors": ["Linlin Zhang", "Daizong Lin", "Xinyuanyuan Sun", "Katharina Rox", "Rolf Hilgenfeld"]}